四川大学华西医学中心，是四川大学的一个介于大学和学院之间的议事机构。下属学院包括： 华西基础医学与法医学院 华西公共卫生学院 华西口腔医学院 华西临床医学院 华西药学院 还包括四所医院：四川大学华西医院、四川大学华西第二医院、四川大学华西第四医院、四川大学华西口腔医院。

During the past decade, West China Hospital conducted 140 clinical trials. In the 10-year time frame, 140 clinical trials started and 20 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 12 clinical trials were completed. i.e. 17.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "West China Hospital" #1 sponsor was "West China Hospital" with 52 trials, followed by "Boehringer Ingelheim" with 18 trials sponsored, "Merck Sharp & Dohme LLC" with 8 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 7 trials sponsored. Other sponsors include 72 different institutions and companies that sponsored additional 65 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "West China Hospital" #1 collaborator was "West China Hospital" with 17 trials as a collaborator, "Eisai Inc." with 4 trials as a collaborator, "Second Affiliated Hospital, School of Medicine, Zhejiang University" with 4 trials as a collaborator, "Anhui Provincial Hospital" with 3 trials as a collaborator and "Fu Wai Hospital, Beijing, China" with 3 trials as a collaborator. Other collaborators include 144 different institutions and companies that were collaborators in the rest 125 trials.

According to Clinical.Site data, the most researched conditions in "West China Hospital" are "Colorectal Cancer" (6 trials), "Non-small Cell Lung Cancer" (6 trials), "Portal Hypertension" (5 trials), "Pulmonary Disease, Chronic Obstructive" (4 trials) and "Coronary Heart Disease" (3 trials). Many other conditions were trialed in "West China Hospital" in a lesser frequency.

Most popular intervention types in "West China Hospital" are "Drug" (100 trials), "Procedure" (19 trials), "Device" (18 trials), "Other" (12 trials) and "Biological" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Pembrolizumab" (6 trials), "Cisplatin" (4 trials), "Lenvatinib" (4 trials) and "Balloon-occluded retrograde transvenous obliteration" (3 trials). Other intervention names were less common.

The vast majority of trials in "West China Hospital" are 157 trials for "All" genders, 6 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are 63 active trials in "West China Hospital". 6 are not yet recruiting, 41 are recruiting, 14 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 60 completed trials in West China Hospital, 2 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in West China Hospital, 14 "Phase 1" clinical trials were conducted, 31 "Phase 2" clinical trials and 52 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 42 trials that are defined as “Not Applicable".

West China Hospital has several departments that took part in Clinical trials: "Department of Critical care medicine of West China Hospital" - 7 trials, "Division of Gastroenterology & Hepatology,West China Hospital,Sichuan University" - 5 trials, "West China Hospital of Sichuan University, Department of Anesthesiology" - 5 trials, "West China Hospital, Sichuan University; Department of Breast" - 5 trials, "Sichuan Province Cancer Hospital/Department of Pulmonary Tumor" - 4 trials, "Oncology Department, West China Hospital of Sichuan University" - 4 trials, "Si Chuan Huaxi Hospital/Rheumatology Department" - 4 trials, "Department of Cardiology, West China Hospital, Sichuan University" - 2 trials, "Department of Respiratory Medicine, West China Hospital of Sichuan University" - 2 trials, "Department of Thoracic Surgery, West China Hospital,Sichuan University" - 2 trials